INmune Bio up on positive data for Alzheimer's drug in animal model

Inmune Bio

19/04/2023 15:51

** Shares of drug developer INmune Bio Inc  INMB.O  rise
1.7% to $8.24
    ** Company reports positive animal study data for its
experimental Alzheimer's disease treatment, XPro
    ** XPro was tested in a mouse model to treat Alzheimer's
disease after it suffered a traumatic brain injury (TBI)
    ** Treatment with XPro one hour after TBI prevents
development of amyloid pathology in brain - company
    ** One key feature of Alzheimer's is the accumulation of a
protein called amyloid in brain, reduction of which can lessen
brain cells damage and improve disease symptoms
    ** Data shows that XPro neutralizes a protein that plays a
role in inflammation and the body's response and drives
development of amyloid pathology after TBI, company says
    ** Stock up 29.9% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))